CAMBRIDGE, MA / ACCESS Newswire / May 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study (NCT05972174) evaluating the safety and ...
The Trump administration has canceled $766 million awarded to drugmaker Moderna Inc. to develop a vaccine against potential pandemic influenza viruses, including the H5N1 bird flu. The company said it ...
The Washington State Department of Health has announced that H5N5, a bird flu strain that has never been detected in humans ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback